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Abstract: Targeting activating mutations in the proto-oncogene B-Raf, in melanoma, has led to increases in progres-
sion free survival. Treatment with vemurafenib, which inhibits the most common activating-mutated form of B-Raf 
(B-RafV600E), eventually results in resistance to therapy. VEGF-A is the principal driver of angiogenesis in primary 
and metastatic lesions. The bioactivity of VEGF-A is dependent upon alternative RNA splicing and pro-angiogenic 
isoforms of VEGF-A are upregulated in many disease states dependent upon angiogenesis, including cancers. Using 
techniques including RT-PCR, Western blotting, ELISA and luciferase reporter assays, the effect of vemurafenib on 
proliferation, ERK1/2 phosphorylation and the levels of pro- and anti-angiogenic VEGF-A isoforms was investigated 
in melanoma cell types expressing either wild-type B-Raf or B-RafV600E, including a primary melanoma culture derived 
from a highly vascularised and active nodule taken from a patient with a V600E mutant melanoma. The primary 
melanoma culture was characterised and found to have reverted to wild-type B-Raf. In B-RafV600E A375 cells ERK1/2 
phosphorylation, pro-angiogenic VEGF-A mRNA, total VEGF-A protein expression and VEGF-A 3’UTR activity were 
all decreased in a concentration-dependent manner by vemurafenib. Conversely vemurafenib treatment of wild-
type B-Raf cells significantly increased ERK1/2 phosphorylation, pro-angiogenic VEGF-A mRNA and total VEGF-A 
expression in a concentration-dependent manner. A switch to pro-angiogenic VEGF-A isoforms, with a concomitant 
upregulation of expression by increasing VEGF-A mRNA stability, may be an additional oncogenic and pathological 
mechanism in B-RafV600E melanomas, which promotes tumor-associated angiogenesis and melanoma-genesis. We 
have also identified the genetic reversal of B-RafV600E to wild-type in an active melanoma nodule taken from a V600E-
positive patient and continued vemurafenib treatment for this patient is likely to have had a detrimental effect by 
promoting B-RafWT activity.
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Introduction 
A substantial proportion of all melanomas con-
tain activating mutations in the proto-oncogene 
B-Raf (50-70%) [1]. Vemurafenib, the most 
common inhibitor of the activating-mutated 
form of B-Raf (B-RafV600E) increases progres-
sion-free survival in melanoma patients but 
eventually resistance to therapy develops and 
disease progression occurs [2]. 
Angiogenesis that results in a functional tumor 
vasculature must develop, in addition to tumor 
cell proliferation, for cancer progression. An- 
giogenesis is driven by the upregulation of pro-
angiogenic molecules of which the vascular 
endothelial growth factor isoform, VEGF-A165 
(herein referred to as VEGF-A165a), is the princi-
pal molecule in primary and metastatic lesions 
[3]. The bioactivity of VEGF-A is dependent upon 
alternative RNA splicing [4, 5] and changes in 
the splicing pattern of VEGF-A are observed in 
many disease states dependent upon angio-
genesis, including cancers [6-8]. Anti-angio- 
genic VEGF-A proteins that contain an alterna-
tive C-terminus (VEGF-Axxxb family), in particular 
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VEGF-A165b, are endogenously expressed in 
normal tissues and downregulated in metastat-
ic melanoma and other cancers [6, 8, 9]. These 
VEGF-Axxxb family proteins competitively antag-
onise the pro-angiogenic signalling of VEGF-
Axxxa and are upregulated in systemic sclerosis 
[10] and obesity [11]. 
Activated B-Raf results in constitutive activa-
tion of extracellular signal-regulated kinase 
1/2 (ERK1/2) and phosphoinositide 3-kinase 
(PI3K) signalling [12]. Inhibition of ERK1/2 sig-
nalling decreases VEGF-A expression and inhib-
its splicing of VEGF-A to pro-angiogenic VEGF-
Axxxa [13] indicating that constitutive B-Raf 
activity may drive tumor-associated angiogen-
esis in melanoma through an effect on the 
expression and/or splicing pattern of VEGF-A. 
We tested the hypotheses that inhibiting B-Raf 
activity in melanoma cells would A) decrease 
VEGF-A expression and B) alter the splicing to 
favour anti-angiogenic VEGF-A. A primary hu- 
man melanoma culture was established from 
an active nodule that had developed resistance 
to vemurafenib therapy. We investigated the 
effect of vemurafenib in these cells and we pro-
pose a novel mechanism of resistance.
Materials and methods
Ethics
Primary human melanoma cells were isolated 
with ethical approval from the Local Ethics 
Committee.
Cell culture
A highly vascularised and active nodule resis-
tant to vemurafenib therapy was removed from 
the anterior chest of a B-RafV600E-positive 
patient and dissociated within 12 h. In brief, 
the tumor was washed, the fat tissue and epi-
dermis were removed and discarded and 
placed into DMEM:F12. The melanoma tissue 
was cut into small (2-5 mm) pieces and enzy-
matically digested (0.125% collagenase P) for 2 
h at 37°C with occasional agitation. Trypsin 
was added (final concentration 0.01% w/v) and 
incubated for 15 minutes. Using a 1 mL pipette 
tip the cells were mechanically dispersed, cen-
trifuged (250 × g-force for 5 minutes) and the 
cell pellet resuspended in DMEM:F12 + 10% 
FBS media. Cells were loaded onto 3 × 15% 
BSA cushion (1 mL 30% BSA in PBS added to 1 
mL DMEM:F12) and centrifuged at 200 × 
g-force for 8 minutes. The cell pellet was resus-
pended in serum-free DMEM:F12 and plated 
into T25 flasks with 2% pen/strep for 48 h, fol-
lowing which media was changed to 10% FBS 
DMEM:F12. A375 (vemurafenib sensitive cuta-
neous melanoma, ATCC), 92.1 vemurafenib 
resistant ocular melanoma and primary mela-
noma cells were grown to ~80% confluence in 
DMEM + 10% FBS before passaging or vemu-
rafenib treatment. All treatments were per-
formed in DMEM + 0.5% FBS.
Reverse transcription PCR
Following 24h vemurafenib treatment, RNA was 
extracted using Trizol as described previously 
[14]. ~1 mg RNA was DNase treated and re- 
versed transcribed with M-MLV reverse tran-
scriptase in the presence of 500 ng Oligo d(T) 
and 250 ng random primers. VEGF-A primers 
(forward 5-GAGCGGAGAAAGCATTTGTT-3, rever- 
se 5-TCAGTCTTTCCTGGTGAGAGAT-3) are desi- 
gned to amplify different exon 8-containing 
VEGF-A mRNA transcripts [15]. Pro-angiogenic 
(exon 8a-containing) and anti-angiogenic (exon 
8b-containing) isoforms produce 201 and 135 
bp PCR products respectively.
Cell proliferation and apoptosis assays
Melanoma cells were treated with vemurafenib 
concentrations for 24 or 48 h in DMEM + 0.5% 
FBS. For proliferation analysis Prestoblue® 
(Life Technologies) was added at the same time 
as vemurafenib and absorbance was read at 
multiple time points over 24 h. Absorbance val-
ues, taken from the logarithmic phase of Pre- 
stoblue® colour development, were used to de- 
termine IC50 values. Apoptosis was measured 
using the commercially available Caspase-3/7-
Glo® (Promega, G8090). 
Transfection
10,000 cells were seeded in a 96 well plate in 
antibiotic-free media and allowed to attached 
(6h). 100 ng plasmid DNA was added per well 
for 24 h (60 ng firefly construct of interest, 40 
ng renilla) following the Effectene transfection 
reagent protocol (Qiagen, 301425). The media 
was removed and vemurafenib concentrations 
were added for 24 h. Luciferase activity was 
measured using Dual-Luciferase Reporter 
Assay (Promega, E1910) following the manu-
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facturers protocol. For each well the Firefly 
luciferase activity (construct of interest) was 
normalised to renilla luciferase activity to con-
trol for differences in transfection and cell 
number. 
Western immunoblotting and ELISA
Protein was extracted in radioimmunoprecipita-
tion assay buffer with protease inhibitor cock-
tail plus 2 mM NaVO4 and 20 mM NaF. For 
immunoblotting, protein was separated by 
SDS-PAGE (12%) and blotted onto polyvinyli-
dene difluoride membrane. This was blocked in 
2% BSA, TBS + Tween 20 (0.05%) for 1 hour, 
and anti-ERK1/2 (rabbit pAb, no.9102, 1 in 
500; Cell Signaling) and anti-phospho-ERK1/2 
(mouse mAb, no.9106, 1 in 250; Cell Signaling) 
were added in blocking solution and incubated 
overnight at 4°C. Fluorescent secondary anti-
bodies (LI-COR, Lincoln, NE) were added 1 in 
10,000 in blocking solution for 1 h at room tem-
perature and fluorescence visualized on a 
LI-COR Odyssey. VEGF-A protein was assayed in 
cell lysate extracts by commercially available 
ELISAs using a VEGF-Axxxb-specific capture anti-
body and a pan-VEGF-A detection antibody for 
VEGF-Axxxb isoforms or two pan-VEGF-A anti-
bodies for total VEGF-A, as previously described 
[16]. As the pan-VEGF-A ELISA has a reduced 
affinity for VEGF-Axxxb compared with VEGF-
Axxxa total VEGF-A levels were determined as 
described previously [16].
Results
The B-Raf exon 15 genetic sequence was deter-
mined for two commercially available melano-
ma cell lines: A375 (primary cutaneous tumor-
derived), 92.1 (uveal melanoma cell line) and 
for a human primary culture (PMEL-NBL) de- 
rived from a highly vascularised and active mel-
anoma nodule resistant to vemurafenib thera-
py (Figure 1A). As previously reported A375 
and 92.1 cell lines contained V600E and wild-
type sequences for exon 15 respectively. PMEL-
NBL contained wild-type B-Raf exon 15 sequ- 
ence. RT-PCR confirmed that the primary cul-
tured cells retained expression of melanocyte/
melanoma-associated markers tyrosinase-rela- 
ted protein-1 (TRP-1), glycoprotein-100 (gp100 
also known as PMEL-17) and melanoma-associ-
ated antigen-3 (MAGE-3) (Figure 1B). TRP-1 and 
MAGE-3 mRNAs were not detected in normal 
human dermal fibroblasts (nHDF). PTEN mRNA 
was detected in all three melanoma cell types. 
The effect of vemurafenib on cell proliferation 
was determined by Prestoblue® analysis 
(Figure 1C and 1D). The proliferation of the two 
wild-type B-Raf cultures (PMEL-NBL culture and 
92.1) was significantly less affected by vemu-
rafenib in comparison with the constitutively 
active B-RafV600E A375 (1-way ANOVA + Bon- 
ferroni *p < 0.05, ***p > 0.001). Vemurafenib 
induced significant apoptosis in A375 cells at 
10 μM but not in wild-type 92.1 (Figure 1E, 
2-way ANOVA + Bonferroni ***p > 0.001). 
ERK1/2 lies downstream of B-Raf signalling. 
Vemurafenib significantly decreased ERK1/2 
phosphorylation in A375 cells, while conversely 
significantly increased ERK1/2 phosphoryla-
tion in the two wild-type cultures (Figure 1F and 
1G, linear regression sig. diff. than 0, ***p > 
0.001). 
The effect of vemurafenib on VEGF-A exon 
8-containing mRNA was investigated in the 
A375 and 92.1 using competitive RT-PCR. 
Increasing concentrations of vemurafenib sig-
nificantly decreased the level of exon 8a-con-
taining mRNA transcripts as detected by 
RT-PCR (Figure 2A and 2B). Conversely, 1 or 10 
µM vemurafenib significantly increased the 
level of exon 8a-containing VEGF-A mRNA tran-
scripts in 92.1 cells (Figure 2A and 2B, 1-way 
Figure 1. Differing effects of vemurafenib on proliferation, apoptosis and ERK1/2 phosphorylation. A. B-Raf exon 
15 was sequenced in three different melanoma cell-types. Cutaneous malignant melanoma-derived A375 contains 
B-RafV600E sequence while uveal melanoma-derived 92.1 and PMEL-NBL, a primary culture derived from an active 
and vascularised nodule contain wild-type B-Raf. B. Expression of melanocyte/melanoma mRNA markers by the 
three melanoma cell types. C&D. The effect of vemurafenib on proliferation was significantly greater on A375 cells 
compared to the wild-type melanoma cell types. E. The effect of vemurafenib on caspase activity was investigated 
in V600E (A375) and wild-type cells (92.1) cells. Vemurafenib had a cytotoxic affect on A375 cells at 10 μM and 
no significant effect on 92.1 cells at any concentration. F&G. Levels of phosphorylated ERK1/2 were detected by 
Western Blotting in A375, 92.1 and PMEL-NBL cells. Vemurafenib significantly reduced ERK1/2 phosphorylation in a 
concentration-dependent manner in A375 while conversely significantly increased ERK1/2 phosphorylation in 92.1 
and PMEL-NBL. Abr: TRP-1, tyrosinase-related protein-1; gp-100, glycoprotein-100; MAGE-3, melanoma-associated 
antigen-3; PTEN, phosphatase and tensin homolog; ERK1/2, extracellular-signal regulated kinase1/2.
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ANOVA + Bonferroni *p > 0.05). No transcripts 
containing exon 8b were detected by RT-PCR 
(Figure 2A) in any of the melanoma cell types 
tested.
To investigate the mechanism by which vemu-
rafenib decreased the level of pro-angiogenic 
VEGF-A mRNA in constitutively active A375 cell 
line, cells were transfected with a plasmid DNA 
construct that contains the 4 kbp promoter 
sequence of VEGF-A upstream of the reporter 
gene, luciferase [17]. In a separate experiment 
A375 cells were transfected with a luciferase 
construct that contains the 3’ untranslated 
region (3’UTR) of the VEGF-A mRNA sequence 
downstream of the luciferase sequence. The 
cells were treated with vemurafenib for 24 h, 
and a change in VEGF-A promoter activity or 
VEGF-A 3’UTR mRNA stability was detected by 
bioluminescence. Increasing concentrations of 
vemurafenib did not significantly affect the 
VEGF-A promoter activity (Figure 2C, 1-way 
ANOVA + Bonferroni, NS not significant). Vemu- 
rafenib did however significantly decrease lucif-
erase activity in cells expressing the 3’UTR 
luciferase construct, in a concentration-depen-
dent manner, indicating that vemurafenib aff- 
ects VEGF-A 3’UTR stability in A375 B-RafV600E 
cells (Figure 2D, 1-way ANOVA, vs. 0 µM, *p > 
0.05. Linear reg. sig. diff. from 0 #p > 0.01).
Total VEGF-A detected in cell lysate protein, as 
detected by ELISA, was decreased by vemu-
rafenib treatment in A375 cells whereas in the 
wild-type cell-types, 92.1 and PMEL-NBL, total 
VEGF-A detected was significantly increased 
(Figure 2E, 2-way ANOVA + Bonferroni, *p > 
0.05). The proportion of total VEGF-A that con-
sisted of pro-angiogenic VEGF-Axxxa was deter-
mined. Vemurafenib significantly decreased 
the proportion of pro-angiogenic VEGF-A in 
A375 cells but significantly increased VEGF-
Axxxa in 92.1 (Figure 2F, 2-way ANOVA + Bon- 
ferroni, vs. 0 µM, *p > 0.05, **p > 0.01). 
Following 0.1 and 1 mM vemurafenib treatment 
of A375 cells, no VEGF-A was detectable in the 
media (Figure 2G). Conversely 1 mM vemu-
rafenib treatment of 92.1 caused a significant 
increase in VEGF-A detected in the media. 10 
mM vemurafenib treatment of A375 cells 
caused a significant increase in VEGF-A detect-
ed in the media presumably as at that concen-
tration the cell were apoptotic (see Figure 1E) 
and VEGF-A would have been released into the 
media from the compromised cells, (Figure 2G, 
2-way ANOVA + Bonferroni, vs. 0 µM, *p > 0.05, 
**p > 0.01, ***p > 0.001). 
The effect of vemurafenib on total and VEGF-
A165b cell lysate protein was investigated by 
Western immunoblotting (Figure 2H) and the 
fluorescence intensity of bands was quantified, 
normalised to respective loading controls and 
expressed as a fold increase over untreated. 
Both total VEGF-A and VEGF-Axxxb were signifi-
cantly decreased in A375 cells by vemurafenib 
treatment (Figure 2I, 1-way ANOVA + Bonferroni, 
vs. con, *p > 0.05). In 92.1 cells, vemurafenib 
did not significantly affect either the total 
VEGF-A or VEGF-Axxxb protein levels detected by 
Western immunoblotting.
Discussion
Mutant B-Raf-driven ERK1/2 MAPK activity is 
implicated in the sustained cancer cell prolifer-
ation that can drive tumor growth. Vemurafenib 
selectively inhibits the constitutively active 
form of B-Raf, B-RafV600E [18] while paradoxi-
cally the drug stabilises and promotes the 
Figure 2. Differing effects of vemurafenib on VEGF-A mRNA and protein. A&B. The effect on vemurafenib on VEGF 
exon 8-containing mRNA transcript expression in A375 and 92.1 cells. Vemurafenib reduced exon 8a containing 
transcripts in a concentration-dependent manner in A375 cells while conversely increased exon 8a containing tran-
scripts in 92.1 cells. C. A375 cells were transfected to overexpress a 4 kb VEGF promoter-luciferase construct. 
Vemurafenib treatment had no significant effect on luciferase activity. D. A375 cells were transfected to overexpress 
a VEGF 3’UTR-luciferase construct. Vemurafenib significantly decreased luciferase activity in a concentration depen-
dent manner. E. Vemurafenib significantly increased total VEGF levels in 92.1 and PMEL-NBL cells but decreased 
it in A375 cells. F. The level of pro-angiogenic VEGF was determined using both pan-VEGF and VEGF-Axxxb ELISAs. 
In wild-type cells vemurafenib increased pro-angiogenic VEGF in a concentration-dependent manner while con-
versely pro-angiogenic VEGF was decreased in V600E A375 cells. G. Vemurafenib significantly increased secreted 
pro-angiogenic VEGF in 92.1 cells but significantly decreased secreted pro-angiogenic VEGF in A375. At 10 μM pro-
angiogenic VEGF was significantly increased in cell media due to increased cell death and lysis. H&I. The effect of 
vemurafenib on VEGF protein was investigated by Western blotting in A375 and 92.1 cells. Vemurafenib decreased 
total VEGF and VEGF-Axxxb protein in A375 cells. In 92.1 cells vemurafenib treatment did not significantly affect total 
VEGF or VEGF-Axxxb protein. Abr: 3’UTR, 3’ untranslated region. 
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activity of wild-type B-Raf [19]. Our results dem-
onstrate that ERK1/2 phosphorylation, pro-
angiogenic VEGF-A mRNA and total VEGF-A pro-
tein expression are decreased by vemurafenib 
treatment in B-RafV600E A375 cells. 3’UTR mRNA 
sequences are known to regulate mRNA stabil-
ity and consequently protein production [20]. 
Vemurafenib treatment significantly decreased 
VEGF-A 3’UTR activity in A375 cells indicating 
an effect on VEGF-A mRNA stability. ERK1/2 
promotes VEGF-A expression [21] and stability 
through the RNA-binding proteins tritetraprolin 
and TIA-1 [20]. Vemurafenib may therefore 
downregulate VEGF-A mRNA levels in B-RafV600E 
cells through inhibition of ERK1/2- TTP or TIA-1 
activity leading to a decrease in VEGF-A mRNA 
stability. Conversely vemurafenib treatment of 
wild-type B-Raf cells significantly increased 
ERK1/2 phosphorylation, pro-angiogenic VEGF- 
A mRNA and total VEGF-A expression as detect-
ed by ELISA. These data support the previous 
published finding that vemurafenib, instead of 
having the desired inhibitory effect, stabilises 
and promotes the activity of wild-type B-Raf. 
Our ELISA data indicate that inhibiting constitu-
tively active B-Raf caused a decrease in the 
proportion of pro-angiogenic VEGF-A while 
vemurafenib did not affect anti-angiogenic 
VEGF-Axxxb in wild-type cells. 
No anti-angiogenic VEGF-A mRNA transcripts 
(exon 8b-containing transcripts) were detected. 
It is worth noting that the competitive nature of 
the PCR will favour one product over the other. 
When 1ng of plasmid VEGF-A165a DNA (pVEGF-
A165a) and 1ng of plasmid VEGF-A165b DNA 
(pVEGF-A165b) were combined for competitive 
PCR, pVEGF-A165a clearly produced a greater 
PCR product than pVEGF-A165b (Figure 2A). 
Therefore the competitive nature of this partic-
ular PCR provides a possible explanation for 
exon 8b containing transcripts not being 
detected. An alternative explanation has been 
provided by the recent work demonstrating that 
translational repression of stop codon usage in 
exon 8a can also result in anti-angiogenic VEGF 
isoforms containing the C-terminal sequence of 
VEGF-Axxxb [22].
We generated a primary human melanoma cul-
ture (PMEL-NBL) from a nodule that had devel-
oped resistance to vemurafenib. TRP-1 and 
gp-100 are expressed by melanocytes and 
melanoma cells [23, 24] and melanoma-asso-
ciated antigen-3 (MAGE-3) expression is swi- 
tched on in many incidence of melanoma [25]. 
PMEL-NBL expressed these 3 mRNAs, and 
TRP-1 and MAGE-3 mRNAs were not detected 
in normal human dermal fibroblast cells, indi-
cating that the primary melanoma culture was 
of melanocyte/melanoma and not from a fibro-
blastic origin. The tumor-suppressor gene PTEN 
is downregulated in many cancers, a process 
thought to be an oncogenic event in melanoma-
genesis [26]. PTEN mRNA expression was 
detected in the PMEL-NBL, indicating that the 
original B-RafV600E-associated oncogenic mech-
anism was not associated with a decrease in 
PTEN mRNA expression. Multiple mechanisms 
of resistance to vemurafenib therapy devel-
oped by cutaneous melanomas in B-RafV600E 
patients have been described but to date none 
have attributed the resistance to a reversal of 
the B-RafV600E genetic sequence to wild-type. 
Our results indicate that the acquired mecha-
nism of resistance to vemurafenib therapy was 
likely due to a genetic reversal of B-Raf from 
V600E to wild-type, or a selection of wild-type 
clones from the original melanoma. With the 
genetic reversal we hypothesise that continued 
treatment with vemurafenib in this patient may 
have the opposite effect to that desired by pro-
moting B-Raf/ERK1/2-driven pro-angiogenic 
VEGF-A signalling in any further undetected 
B-Raf wild-type nodules. Our data indicates 
that a switch to pro-angiogenic VEGF-A iso-
forms, with a concomitant upregulation of 
expression by increasing VEGF-A mRNA stabili-
ty, may be a major oncogenic and pathological 
mechanism in B-RafV600E melanoma that pro-
motes tumor-associated angiogenesis and 
melanomagenesis.
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